Enzyme activities as a predictor of diabetic vasculopathy.
Forty-one patients with chemical diabetes had three oral glucose tolerance tests and underwent muscle biopsy three times over a period of three years. Twenty-three received glipizide and 18 placebo. Those taking placebo had an increase in the mean muscle capillary basement membrane width (p = 0.01), but those taking glipizide showed a decrease (p = 0.01) to values no different from those of nondiabetic subjects. Determinations of enzyme activities involved in the synthesis and degradation of glycoproteins revealed a three-year decrease (not significant) in muscle glucosyltransferase activity in the glipizide-treated patients, but a statistically significant difference (p less than 0.01) comparing the adjusted means of the two treatment groups. N-acetyl-beta-glucosaminidase activity was significantly increased in muscle from baseline values (p less than 0.01), with adjusted means also significantly different (p less than 0.01). The data suggest that changes in basement membrane and enzyme activities are correlated, and the latter may be a predictor to follow the development, progression, or regression of diabetic vasculopathy.
D000118:Acetylglucosaminidase / Q000032:analysis* / Q000097:blood; D000328:Adult; D001485:Basement Membrane / Q000648:ultrastructure; D002196:Capillaries / Q000473:pathology; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D005260:Female; D005913:Glipizide / Q000627:therapeutic use; D005964:Glucosyltransferases / Q000032:analysis* / Q000097:blood; D006596:Hexosaminidases / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000201:enzymology; D010919:Placebos
D010919:Placebos; D005964:Glucosyltransferases; D006596:Hexosaminidases; D000118:Acetylglucosaminidase; D005913:Glipizide